TD Cowen analyst Tyler Van Buren has maintained their bullish stance on ACLX stock, giving a Buy rating yesterday.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Tyler Van Buren has given his Buy rating due to a combination of factors that highlight the promising outlook for Arcellx Inc. The company’s anito-cel therapy has demonstrated a best-in-class profile, with a progression-free survival (PFS) rate that matches a leading competitor, Carvykti, despite having a shorter follow-up period. This suggests potential for even better performance as more data becomes available.
Additionally, the anticipated Biologics License Application (BLA) filing and the clean safety profile of anito-cel are significant positive indicators. The absence of serious adverse events, such as Parkinsonism, enhances the therapy’s value proposition and could lead to a favorable regulatory review. These elements collectively contribute to a strong launch potential, supporting Van Buren’s Buy recommendation for Arcellx Inc.
According to TipRanks, Van Buren is an analyst with an average return of -2.2% and a 41.79% success rate. Van Buren covers the Healthcare sector, focusing on stocks such as Regeneron, Moderna, and Soleno Therapeutics.